123 related articles for article (PubMed ID: 3478535)
1. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Gustavsson A; Olofsson T
Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
[TBL] [Abstract][Full Text] [Related]
3. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Yang GS; Minden MD; McCulloch EA
Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
[TBL] [Abstract][Full Text] [Related]
4. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
[TBL] [Abstract][Full Text] [Related]
7. Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
Zittoun R; Marie JP; Brilhante D; Delmer A
Haematol Blood Transfus; 1987; 30():45-9. PubMed ID: 3476378
[No Abstract] [Full Text] [Related]
8. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
9. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance.
Curtis JE; Messner HA; Minden MD; Lipton JH; Lockwood GA; Tritchler DL; McCulloch EA
Leukemia; 1992 Nov; 6(11):1192-8. PubMed ID: 1434804
[TBL] [Abstract][Full Text] [Related]
11. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
12. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
13. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties.
Delmer A; Marie JP; Thevenin D; Cadiou M; Viguié F; Zittoun R
J Clin Oncol; 1989 Jun; 7(6):738-46. PubMed ID: 2715804
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
17. [The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Parovichnikova EN; Kliasova GA; Sokolov AN; Troitskaia VV; Kokhno AV; Kuz'mina LA; Shaforostova II; Ryzhko VV; Kravchenko SK; Bondarenko SN; Lapin VA; Pristupa AS; Konstantinova TS; Zagoskina TP; Ialykomov IV; Moskov VI; Anchukova LV; Kaporskaia TS; Volodicheva EM; Kaplanov KD; Kondakova EV; Samoĭlova OS; Gavrilova LV; Kulikov SM; Savchenko VG
Ter Arkh; 2012; 84(7):10-5. PubMed ID: 23038965
[TBL] [Abstract][Full Text] [Related]
18. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
19. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
